Colorectal Cancer Gene Mutation and Methylation Panel, NGS (OptiSeq™, Shield™)
Colorectal cancer is one of the most common malignancies worldwide. It arises from epithelial cells lining the colon or rectum, most often beginning as adenomatous polyps that can undergo malignant transformation over time. Prognosis strongly depends on stage at diagnosis: patients with stage I disease have a 5-year survival rate of about 91%, compared with only 14% for those with stage IV disease. This underscores the importance of early detection and accurate molecular profiling for guiding treatment.
The OptiSeq™ Colorectal Cancer Gene Panel is a multiplex next-generation sequencing (NGS)–based liquid biopsy assay that evaluates both genetic mutations and DNA methylation markers associated with colorectal cancer. Specifically, it interrogates 462 alterations across 43 genes and 432 CpG sites spanning 61 genomic regions across 45 methylation markers. This panel includes clinically relevant targets such as KRAS, NRAS, BRAFV600E, ERBB2, and microsatellite instability (MSI), consistent with NCCN guidelines for metastatic colorectal cancer management. For more visit: https://www.diacarta.com/services/optiseq-ngs-targeted-sequencing
The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with positive results should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc., for more see https://shieldcancerscreen.com/
- Assists in early diagnosis and prognosis assessment.
- Aids in screening average-risk individuals (Shield™)
- Supports therapeutic decision-making, including selection of immunotherapy
- Useful for risk stratification in patients with a family history of colorectal cancer
Negative (No mutations/ pathogenic variants or abnormal methylation markers detected)
Whole Blood, EDTA.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 30 days
- Int J Mol Sci. 2018 Oct 26;19(11):3356. [PMID: 30373199]
- Mol Oncol. 2021 Oct;15(10):2702-2714. [PMID: 33694305]
- J Gen Intern Med. 2018;33(12):2100-2105. [PMID: 30284171]
- Mol Cancer. 2024 Jan 3;23(1):1. [PMID: 38172877]